Intech Investment Management LLC Makes New $329,000 Investment in Certara, Inc. $CERT

Intech Investment Management LLC bought a new stake in Certara, Inc. (NASDAQ:CERT) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 28,147 shares of the company’s stock, valued at approximately $329,000.

Several other large investors have also recently bought and sold shares of CERT. AdvisorNet Financial Inc acquired a new stake in shares of Certara in the second quarter valued at $25,000. Caitong International Asset Management Co. Ltd bought a new stake in Certara in the first quarter worth about $31,000. AlphaQuest LLC acquired a new stake in Certara in the 1st quarter valued at about $39,000. ANTIPODES PARTNERS Ltd boosted its position in shares of Certara by 22.5% during the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 6,665 shares of the company’s stock valued at $78,000 after purchasing an additional 1,223 shares in the last quarter. Finally, Quarry LP bought a new position in shares of Certara during the 1st quarter valued at about $98,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Trading Up 0.2%

Certara stock opened at $9.16 on Monday. Certara, Inc. has a 12 month low of $8.02 and a 12 month high of $15.69. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27. The stock has a market cap of $1.46 billion, a P/E ratio of 130.79 and a beta of 1.44. The company’s fifty day simple moving average is $11.06 and its 200-day simple moving average is $11.03.

Certara (NASDAQ:CERT) last posted its earnings results on Thursday, November 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.11 by $0.03. Certara had a net margin of 2.62% and a return on equity of 5.18%. The firm had revenue of $104.62 million for the quarter, compared to the consensus estimate of $104.53 million. During the same period in the prior year, the business posted $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. As a group, sell-side analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Insider Transactions at Certara

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total value of $559,366.08. Following the completion of the sale, the insider owned 73,979 shares in the company, valued at approximately $807,850.68. This trade represents a 40.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.33% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CERT. Barclays cut their target price on shares of Certara from $16.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, November 7th. Rothschild & Co Redburn began coverage on Certara in a research report on Friday, November 21st. They set a “buy” rating and a $10.00 price objective for the company. Redburn Partners set a $10.00 target price on Certara in a report on Friday, November 21st. Wall Street Zen raised Certara from a “hold” rating to a “buy” rating in a research report on Monday, November 24th. Finally, Zacks Research upgraded Certara from a “strong sell” rating to a “hold” rating in a research report on Friday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $13.82.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.